Navigation Links
BGI reports study results on frequent mutation of genes encoding UMPP components in kidney cancer
Date:12/4/2011

December 4th, 2011, Cambridge, MA and Shenzhen, China BGI, the world's largest genomics organization, announced that a study on frequent mutation of genes encoding ubiquitin-mediated proteolysis pathway (UMPP) components in clear cell renal cell carcinoma (ccRCC) is published online today in Nature Genetics. In addition to BGI, co-leaders of the study included Peking University Shenzhen Hospital, Shenzhen Second People's Hospital, among others. The study reveals that alteration of UMPP may contribute to ccRCC by activation of the hypoxia regulatory network, providing new clues to trace the key molecular mechanisms and pathways that underlie the tumorigenesis and progression of ccRCC.

Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive type of kidney cancer, with 102,000 deaths worldwide each year. It is characterized by high metastatic potential and poor prognosis. Up to 40% of patients have disease recurrence after nephrectomy. In this study, the research team specifically looked at alterations in ubiquitin-mediated proteolysis pathway and studied its potential impacts linked to ccRCC tumorigenesis. The UMPP has been reported to be associated with many diseases including cancer and plays a critical role in the protein metabolism as a major pathway for protein degradation in cells.

"Adding to the previous research effort of transitional cell carcinoma in bladder cancer published in Nature Genetics earlier this year, we and our partners continued our study of strongly aggressive ccRCC tumors to identify the mutated genes associated with the process of tumorigenesis," said Guangwu Guo, one of the co-leading authors of the study and PI of this project at BGI. "The new discoveries in this study led us to a remarkable step in our understanding of the genetic landscape of ccRCCs and toward potential treatment against this aggressive tumor."

To gain a deep insight into the genetic basis of ccRCC, researchers analyzed ten primary tumors with matched morphologically normal renal tissues utilizing the whole exome sequencing approach on BGI's sequencing platform. The mutation prevalence was estimated by screen of ~1,100 genes with somatic mutations or that have been causally implicated in cancers in 88 additional ccRCCs for prevalence screen.

There were 23 significantly mutated genes identified in the 98 ccRCCs, including the five well-known renal cancer genes such as VHL and TP53, and genes involved in chromatin modification such as PBRM1, JARID1C and SETD2. "We have identified 12 genes which were previously unknown to be involved in ccRCC, including two tumor suppressor genes, BAP1 and TSC1. Integration of previous studies and our findings suggest that some of the genes may play important roles in ccRCC genesis," said Guo.

In addition to the attempt to identify all mutated genes associated with ccRCC, researchers also focused on specific genes, pathways and mechanisms that potentially play a key role in ccRCC tumorgenesis and warrant exploration as potential targets for treatments. One of the targets was mutations in VHL gene that were commonly suggested to be involved in ccRCC genesis in many previous genetic studies with reported prevalence ranging between 50% and 80%. Interestingly, researchers have found a much lower prevalence of 27% in this study. VHL promoter hypermethylation was only found in 6% of the tumors relative to their matched normal samples, also suggesting a lower prevalence of epigenetic VHL alternation, according to the researchers.

Although the alteration of VHL gene is widely known for its association with kidney cancer, researchers also revealed the frequent mutation of UMPP linked to ccRCC in this study and have sequenced all 135 genes in UMPP in the prevalence screen. A significantly high mutation frequency of UMPP was found in the 98 carcinoma samples. The pathway analysis suggested that alternation of UMPP could potentially play an important role in ccRCC tumorigenesis, and it may contribute by activating the hypoxia regulatory network.

"This study has enhanced our knowledge and laid an important foundation for future research of ccRCC. The new discovery on the potential contribution of UMPP to ccRCC justifies more comprehensive investigation of this pathway, including proteomics research of the protein network to fully elucidate its role in ccRCC genesis," said Professor Jun Wang, Executive Director of BGI.


'/>"/>

Contact: Jia Liu
liujia@genomics.cn
BGI Shenzhen
Source:Eurekalert

Related biology news :

1. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
2. GEN reports on novel tools for deciphering biological networks
3. Synaptics Reports Record Results for First Quarter of Fiscal 2009
4. Communication Intelligence Corporation Reports Third Quarter 2008 Financial Results
5. Orchid Cellmark Reports Third Quarter 2008 Financial Results
6. Genetic Engineering & Biotechnology News reports on the trend toward predictive toxicogenomics
7. GEN reports growing focus on PI3-kinase pathway in cancer research
8. Cytori reports benefit of adipose-derived regenerative cells in spinal disc model
9. GEN reports on growing reliance on microfluidics technology
10. GEN reports on strategies to overcome blood-brain barrier
11. Aware, Inc. Reports Fourth Quarter and 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):
(Date:7/24/2017)... Intralytix, Inc. announced that it received $17.5 million in ... This investment marks the beginning of a close collaboration ... for various benefits in human health and in other ... As a global key player in yeasts ... for baking, food taste & pleasure, health care, and ...
(Date:7/24/2017)... FL (PRWEB) , ... July ... ... Strategic Analyst, Kenny Soulstring, today announced that the stock market news outlet ... in risk assessment diagnostic testing that screens and identifies exposure, progression and ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... leading radiology and imaging centers around the U.S. that offer MR Elastography for ... alternative to needle biopsy for staging liver fibrosis assessment. , “MRE:connect was ...
(Date:7/20/2017)... ... July 20, 2017 , ... Litmus Health ... announced its full advisory board. The board comprises leaders spanning business, technology, academia, ... PhD, former VP of Engineering, to Chief Technology Officer. Crooks will lead strategy ...
Breaking Biology Technology: